partnering with eli lilly and company. lilly at a glance founded in 1876 in indianapolis, indiana...

Partnering with Eli Lilly and Company

Lilly at a GlanceLilly at a Glance

Founded in 1876 in Indianapolis, Indiana

$18.71B sales in 2007

40,600 employees worldwide

Operations in 87 countries and sales in 138 countries

Award winning culture:– Fortune magazine “100 best Companies to Work

for”– Industry Week “100 Best-Managed Companies”– Science Magazine Best Company for Scientists– Forbes.com “The 75 most Reputable Companies in

the US”

Copyright © 2009 Eli Lilly and Company 2

Lilly Global PresenceLilly Global Presence

San Diego: Bioproduct

R&D

Indianapolis: Global R&D HQ

Canada: Bioproduct Analytical R&D

Australia: Drug Discovery R&D

Singapore: Drug Discovery and

Biomarker R&D

Japan: ADME R&D

China: Drug Discovery R&D

Spain: Medicinal Chemistry

United Kingdom: Neuroscience

Research


Areas of Strategic FocusAreas of Strategic Focus

NeuroscienceNeuroscienceOncologyOncology

CardiovascularCardiovascularEndocrineEndocrine

MusculoskeletalMusculoskeletal

Image and Text Copyright © 2008 Photo Researchers, Inc.

All Rights Reserved.






Key Innovation PlatformsKey Innovation Platforms

Small Molecule

Antibody

PeptideProtein

Antisense

BioProducts


Lilly Recombinant Protein ProductsLilly Recombinant Protein Products


The Lilly Development TeamsThe Lilly Development Teams


Neuroscience Mission StatementNeuroscience Mission Statement

To improve the lives of people

suffering from psychiatric and

neurological disorders with

innovative therapeutic advances.


Neuroscience: Areas of InterestNeuroscience: Areas of Interest

Innovative Molecules and Programs in:• Schizophrenia• Depression• Anxiety disorders• Bipolar disorders• Sleep disorders• Substance abuse (e.g.. Alcoholism)• Cognitive dysfunction• Alzheimer’s and Parkinson’s disease

– Focused on approaches that affect disease progression or modification• Pain

– Neuropathic and inflammatory• Migraine

– Prophylaxis and acute treatment– Non-vasoconstrictive approaches

• Multiple sclerosis


Lilly’s Neuroscience Clinical Development Lilly’s Neuroscience Clinical Development CompoundsCompounds

Regulatory Review

Olanzapine depot DA/5-HT2 antagonist Schizophrenia

Formulation

Phase III

NERI IV Norepinephrine reuptake inhib. Depression, ADHD

Dirucotide Immunological Tolerance Multiple Sclerosis

LY-450139 Gamma-secretase inhibitor Alzheimer’s Disease

Phase II

Abeta antibody Passive immunization Alzheimer’s Disease

mGlu2/3 agonist mGlu2/3 agonist Schizophrenia

LY2624803 5HT-2a ant. / H1 inverse agonist Insomnia

mGluR3 mGluR3 antagonist Migraine

GRC-6211 Vanilloid receptor 1 antagonist Osteoarthritic pain

Phase I

OPRA II Opioid receptor antagonist Alcoholism

iGluR5 antagonist iGluR5 antagonist PainCopyright © 2009 Eli Lilly and Company 10

Technology Needs - NeuroscienceTechnology Needs - Neuroscience

1. Predictive biomarkers of any nature (e.g., genetic, proteomics, metabolic, other biochemical, biological, morphological)

2. Predictive animal models


Lilly Knows From Experience ThatLilly Knows From Experience ThatPartnering Supports Future GrowthPartnering Supports Future Growth

arzoxifene

'00 ‘01 ‘02 ‘03 ‘04 ‘05 ’06 ’07 ‘08

Prasugrel

enzastaurin

LY-517717

LY-2181308

LY-450139

LY-2599506

LY-2624803

ArxxantTM

ruboxistaurin

Teplizumab

Exenatide LAR

NERI IV

GRC-6211MBP-8928

Eg5


External Innovation at LillyExternal Innovation at Lilly


partnering with eli lilly and company. lilly at a glance founded in 1876 in indianapolis, indiana...

Documents